STAP2

Across TCGA pan-cancer cohorts, STAP2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated STAP2 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher STAP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STAP2 expression acts as an unfavorable survival marker, although some lineages such as COAD and UCEC show a favorable association.

COAD, UCEC, and LSCC are the cancer types where STAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	1.000	0.891	.027	30	view →
UCEC	DFS	Median	All	0.973	0.839	.006	26	view →
LSCC	DFS	Median	II,III,IV	1.000	0.836	.005	21	view →
PDAC	DFS	Median	All	0.448	0.209	.003	20	view →
LUAD	DFS	Tertile	All	0.452	0.734	.020	8	view →
HNSC	OS	Median	All	1.000	0.497	.046	4	view →
GBM	OS	Median	All	0.472	0.763	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

STAP2–COAD (DFS)

Open the COAD breakdown →